2026 年 02 月 09 日 王睿哲 C0062@capital.com.tw 目标价(港币) 98 公司基本资讯 | 产业别 | | 医药生物 | | --- | --- | --- | | H 股价(2026/02/06) | | 79.50 | | 恒生指数(2026/02/06) | | 26560.00 | | 股价 12 个月高/低 | | 107.00 / 33.05 | | 总发行股数(百万) | | 1735.19 | | H 股数(百万) | | 1735.19 | | H 市值(亿港币) | | 1379.47 | | 主要股东 | | 俞德超(5.36%) | | 每股净值(港币) | | 9.8324 | | 股价/帐面净值 | | 8.0855 | | | 一个月 三个月 | 一年 | | 股价涨跌(%) | -10.97 -6.69 139.82 | | 近期评等 | 出刊日期 | 前日收盘 | 评等 | | --- | --- | --- | | 2025/10/22 | 88.00 | 买进 | | 产品组合 | | | --- | --- | | 药品销售 | 87% ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Insights - The company is expected to achieve a net profit of 2.15-2.25 billion yuan for FY26H1, representing a year-on-year increase of 216%-231%. After considering perpetual bonds, the attributable net profit is projected to be 1.95-2.05 billion yuan, reflecting a year-on-year growth of 315.2%-336.5%. This strong performance is primarily due to increased product sales volume, rising sales prices, and a decrease in raw material costs leading to a significant increase in gross profit [1] - The scale effect of pulp production is becoming evident, with the company's pulp production capacity in Guangxi coming online. This has resulted in a rapid reduction in pulping costs and an increase in the self-supply ratio of pulp, which are key factors driving the company's performance beyond expectations [2] - The pulp segment is contributing significantly to profits, while the waste paper segment is showing improvement in profitability. Despite cultural and white card paper prices being at historical lows, the company is still able to generate profit increments due to its self-produced pulp advantage. By FY25, the company’s production capacity for white card and cultural paper is expected to reach 1.8 million and 2.27 million tons, respectively, with further expansions planned for FY26H1 [3] - The company continues to expand its pulp production capacity, with total pulp capacity reaching 23.5 million tons by FY25. The focus remains on increasing the self-supply ratio of raw materials, with additional production capacity planned for FY26 and FY27. This ongoing expansion is expected to further enhance the company's profitability [4] Financial Summary - Revenue projections for FY26-FY28 are 72.67 billion, 73.99 billion, and 74.76 billion yuan, representing year-on-year growth of 15%, 2%, and 1%, respectively. The attributable net profit is forecasted to be 4.08 billion, 4.41 billion, and 5.04 billion yuan, with year-on-year increases of 131%, 8%, and 14%, respectively. The corresponding P/E ratios are 8.9, 8.3, and 7.2 times [4][9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Insights - The company is expected to achieve a net profit of 2.15-2.25 billion yuan for FY26H1, representing a year-on-year increase of 216%-231%. After considering perpetual bonds, the attributable net profit is projected to be 1.95-2.05 billion yuan, reflecting a year-on-year growth of 315.2%-336.5%. This strong performance is primarily due to increased product sales volume, rising sales prices, and a decrease in raw material costs leading to a significant increase in gross profit [1] - The scale effect of pulp production is becoming evident, with the company's pulp production capacity in Guangxi contributing to a rapid reduction in production costs and an increase in the self-supply ratio of pulp, which are key factors driving the company's performance above expectations [2] - The pulp segment is contributing significantly to profits, while the waste paper segment is showing improvement in profitability. Despite cultural and white card paper prices being at historical lows, the company is still able to generate profit growth due to its self-produced pulp advantages [3] - The company continues to expand its pulp production capacity, with total pulp capacity reaching 23.5 million tons by FY25. The focus on increasing the self-supply ratio of raw materials is expected to further enhance profitability. The company has plans to build additional chemical pulp production facilities in Chongqing and Tianjin, with expected production increases in the coming years [4] Financial Forecast and Valuation - The company is projected to achieve revenues of 72.67 billion yuan, 74 billion yuan, and 74.76 billion yuan for FY26, FY27, and FY28, respectively, with year-on-year growth rates of 15%, 2%, and 1%. The attributable net profit is expected to be 4.08 billion yuan, 4.41 billion yuan, and 5.04 billion yuan for the same periods, with year-on-year growth rates of 131%, 8%, and 14%. The corresponding P/E ratios are 8.9, 8.3, and 7.2 [4][9]

证券研究报告 | 2026年02月09日 中国东方教育（00667.HK） 优于大市 模式升级固本培元，职教龙头弄潮服务消费新风口 深耕职教近四十年，多品牌构筑技能培训版图。中国东方教育是国内领先的 职业技能教育集团，旗下布局新东方烹饪、新华电脑、万通汽修等知名品牌。 2019 年在港股上市。公司覆盖烹饪技术、西点西餐、信息及互联网技术、汽 车服务四大成熟专业，并积极布局美业、宠物、康养等新兴专业。 技能培训行业：职教万亿扩容，中职调整寻机。我国职业教育行业处于万亿 扩容黄金期，受政策持续加码与产业需求拉动双轮驱动，2025-2029 年预计 维持 17%复合增速，2029 年市场规模有望突破 2 万亿元。此前中职赛道经历 数年调整，2010-2024 年在高中招生占比从 51%下滑至 34%，但考虑中级技能 人才产业刚需、部分普高适配度较低学生回流，后续普高比有望寻找新平衡。 成熟专业：疫后盈利能力率先修复，收入后提速打开利润增长空间。2024 年以来公司积极调整，关停并转低效校区、推进五省职教产业园建设、升级 课程结构，带动 2025H1 公司经调净利率 19.0%/+5.0pct；预计伴随更多职教 园区 ...

2026 年 02 月 09 日 王睿哲 C0062@capital.com.tw 目标价(港币) 98 近期评等 | 出刊日期 | 前日收盘 | 评等 | | --- | --- | --- | | 2025/10/22 | 88.00 | 买进 | | 产品组合 | | | --- | --- | | 药品销售 | 87% | | 企业授权产品 | 12% | | 研发收入 | 1% | 股价相对大盘走势 C o m p a n y U p d a t e C h i n a R e s e a r c h D e p t . 信达生物 (01801.HK) 买进（Buy） 公司基本资讯 | 产业别 | | 医药生物 | | --- | --- | --- | | H 股价(2026/02/06) | | 79.50 | | 恒生指数(2026/02/06) | | 26560.00 | | 股价 12 个月高/低 | | 107.00 / 33.05 | | 总发行股数(百万) | | 1735.19 | | H 股数(百万) | | 1735.19 | | H 市值(亿港币) | | 1379.47 ...

Investment Rating - Kuaishou Technology is rated as BUY with a target price of HK$80.00 [6][7][8] - WeRide Inc. is also rated as BUY with a target price of US$13.00 for ADR and HK$34.00 for its Hong Kong shares [9][10][13] Core Insights - Kuaishou Technology is expected to achieve a 10% year-on-year revenue growth in 4Q25, with an adjusted net profit of RMB5.4 billion [6][8] - Despite short-term pressures from stricter tax scrutiny and intense competition, Kuaishou's long-term monetization potential is bolstered by its AI initiatives and ecosystem integrations [6][7][8] - WeRide Inc. anticipates a significant revenue increase of over 70% quarter-on-quarter in 4Q25, driven by growth in its Robotaxi and Robobus segments [9][10][13] - The company aims to double its Robotaxi fleet to over 2,000 units by the end of 2026, with a focus on key markets in China and international expansion in the Middle East [10][11][13] Summary by Sections Kuaishou Technology - The company is projected to have a revenue increase of 10% year-on-year for 4Q25, with an adjusted net profit of RMB5.4 billion [6][8] - Long-term monetization potential is supported by AI developments and integration with core business ecosystems [6][7][8] WeRide Inc. - Expected revenue for 4Q25 is projected to be between RMB290 million and RMB300 million, with a full-year revenue forecast of RMB660 million to RMB670 million [9][10][13] - The gross margin is anticipated to remain above 30%, although increased R&D spending may impact net profits [9][10][13] - The company plans to expand its Robotaxi fleet significantly, with a strategic focus on both domestic and international markets [10][11][13]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [4] Core Insights - The company reported strong same-store sales performance in Q4 2025, with a revenue of $2.82 billion, representing a 9% year-on-year growth, and a net profit of $140 million, up 24% year-on-year [6] - The company aims to exceed 30,000 stores by 2030, having reached 18,101 stores by the end of 2025, with a net addition of 1,706 stores during the year [6] - The company plans to return $1.5 billion to shareholders through dividends and buybacks in 2026, with an average annual return of approximately $900 million to over $1 billion in 2027 and 2028 [6] - The company is expected to achieve net profits of $1.071 billion, $1.156 billion, and $1.242 billion for 2026, 2027, and 2028 respectively, with corresponding growth rates of 15%, 8%, and 8% [6] Financial Performance - For 2024, the company forecasts revenue of $11.303 billion, with a year-on-year growth rate of 3% [5] - The projected earnings per share (EPS) for 2026 is $3.02, with a return on equity (ROE) of 21.6% [5] - The price-to-earnings (P/E) ratio is expected to be 18.53 for 2026, indicating a stable valuation [5]

Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company held its annual meeting on February 6, outlining strategic directions for 2026 and highlighting significant achievements from 2025. The company expects strong performance in the new year, driven by new product launches and the long-term commercial value of its IP operation platform [2][3] - The company anticipates substantial revenue growth, with LABUBU's annual sales expected to exceed 100 million units and total product sales across all categories projected to surpass 400 million units in 2025. The average price of products is over 100 yuan [3] - The company is expanding its business to over 100 countries and regions, with more than 700 global stores, and has solidified its supply chain capabilities with six major supply chain bases [3] - New products have performed well, with significant growth in GMV on domestic platforms like Douyin. The company has launched several new series, which are expected to support strong performance in the new year [4] - The company is diversifying its IP portfolio, establishing a "Pop Mart brand universe" that includes amusement parks, desserts, jewelry, and entertainment [5] Financial Projections - Revenue projections for 2025-2027 are 38.38 billion, 52.77 billion, and 65.70 billion yuan, respectively. Net profit estimates for the same period are 13.29 billion, 18.60 billion, and 23.91 billion yuan, with EPS expected to be 9.91, 13.86, and 17.82 yuan [6][8] - The company maintains a gross margin of approximately 71% in the forecast period, with a projected PE ratio decreasing from 22 to 12 over the same period [8]

Investment Rating - The report recommends a focus on the company, indicating that it is undervalued with a reasonable valuation range of over HKD 25 billion [21]. Core Insights - The company has transitioned from traditional generic drugs to a dual-driven strategy focusing on "aesthetic medicine and innovative drugs," leading to a significant revenue increase in the aesthetic segment [21]. - The aesthetic medicine segment saw a revenue increase of 81% year-on-year in the first half of 2025, contributing significantly to the company's overall revenue growth [4][11]. - The innovative drug segment is expected to enter a revenue realization phase with the commercialization of new drugs, enhancing the company's financial outlook [12][16]. Summary by Sections Aesthetic Medicine - In H1 2025, aesthetic medicine revenue increased by 81% to HKD 5.9 billion, with a gross margin improvement of 8 percentage points to 73% [4][11]. - The core product, Letybo (botulinum toxin), has a market penetration of less than 2% in China, indicating substantial growth potential compared to higher penetration rates in the US and South Korea [5]. - The company has three major products approved in 2025, including facial fillers and water light needles, which are expected to drive significant sales growth [9][10]. Innovative Drugs - The innovative drug segment reported a 30% revenue increase to HKD 0.17 billion in H1 2025, with a focus on gastrointestinal and oncology treatments [12]. - The company has successfully commercialized its first innovative PPI drug, which is expected to maintain its price in the national basic medical insurance directory [12][14]. - The company holds a 49.13% stake in Xuan Zhu Bio, which has a market capitalization of HKD 34.5 billion, further enhancing its financial position [12]. Biopharmaceuticals - The biopharmaceutical segment, focusing on diabetes, has a comprehensive pipeline with over 20 products, and revenue is expected to see explosive growth in the next 2-3 years [17][18]. - The company reported a 40-fold increase in revenue to HKD 0.39 billion in H1 2025, with a focus on insulin and innovative diabetes treatments [17][18]. Generic Drugs - Generic drug revenue decreased by 16% to HKD 5.0 billion in H1 2025, accounting for 44% of total revenue, but the impact is expected to lessen as aesthetic and innovative drug segments grow [19]. - Key products include Clinao (a unique injection) and a mucosal solution for children, which are positioned to capture niche markets [19]. Profit Forecast - The company is expected to turn profitable in 2025, with significant revenue growth driven by aesthetic and innovative drugs, alongside reduced R&D expenses [20]. - The company has maintained a high dividend payout ratio of 89% in H1 2025, reflecting strong cash flow management [20].

Investment Rating - The report initiates coverage with a "Buy" rating for the company [2][56]. Core Insights - The company is a leading player in the snack retail industry, with significant growth in revenue and profit projected for the coming years. Revenue is expected to reach RMB 656.97 billion in 2025, RMB 837.49 billion in 2026, and RMB 925.80 billion in 2027, with corresponding growth rates of 66.98%, 27.48%, and 10.54% respectively. Net profit is forecasted to be RMB 23.01 billion, RMB 34.23 billion, and RMB 42.85 billion for the same years, reflecting growth rates of 176.05%, 48.73%, and 25.19% respectively [2][56]. Summary by Sections Company Overview - The company, founded in 2016, has rapidly expanded its store count to 21,041 by November 2025, with 59% of stores located in county and town areas. The company achieved a GMV of RMB 555 billion in 2024 and RMB 661 billion in the first three quarters of 2025, marking year-on-year increases of 262% and 74% respectively [7][15]. Store Expansion and Performance - The company has seen a continuous increase in store numbers, from 1,902 in 2022 to 21,041 by November 2025. The average daily order volume per store has also risen from 385 to 481 orders during the same period, with a year-on-year increase of 4.1% [15][21]. Financial Performance - The company reported revenues of RMB 393.4 billion and RMB 463.7 billion for 2024 and the first three quarters of 2025, respectively, with year-on-year growth of 282% and 75%. Net profits for the same periods were RMB 8.29 billion and RMB 15.59 billion, reflecting growth rates of 281% and 219% [43][44]. Profitability Metrics - The company's net profit margin improved from 1.67% in 2022 to 3.36% in the first three quarters of 2025. The adjusted net profit margin also increased from 1.90% to 3.90% during the same period, indicating enhanced profitability [44][56]. Future Projections - The report forecasts significant revenue and profit growth for the company, with expected revenues of RMB 656.97 billion, RMB 837.49 billion, and RMB 925.80 billion for 2025, 2026, and 2027, respectively. The corresponding net profits are projected to be RMB 23.01 billion, RMB 34.23 billion, and RMB 42.85 billion [2][56].